SHANGHAI – A year after China introduced an amended patent law, authorities have revoked the patent on Gilead Science Inc.'s HIV/AIDS and hepatitis B drug Viread (tenofovir disoproxil fumarate). Read More
Skittish investors seemed more worried than analysts about word from Halozyme Therapeutics Inc. and Viropharma Inc. that the Phase II study will be discontinued with subcutaneous Cinryze (C1 esterase inhibitor with recombinant hyaluronidase [rHuPH20]) for hereditary angioedema (HAE) because of high levels of non-neutralizing antibodies. Read More
With drug-resistant superbugs outracing the pace of today's antibiotic development, medical experts are pushing Congress to create a regulatory superhighway specifically for drugs intended to head off the worst of the worst bugs. Read More
Karyopharm Therapeutics Inc. added to its impressive Series B commitment with a $19 million extension led by new investor Foresite Capital Management, with additional participation by New Leaf Venture Partners and an unnamed top-tier institutional investor and by current investor Delphi Ventures. Read More
• Omeros Corp., of Seattle, said it submitted a new drug application for use of OMS302 in patients undergoing intraocular lens replacement surgery. Read More
• Brainstorm Cell Therapeutics Inc., of New York, said it submitted a favorable safety report to the hospital Helsinki Committee for the second group of patients in its ongoing Phase IIa amyotrophic lateral sclerosis (ALS) study. Read More
• Amag Pharmaceuticals Inc., of Lexington, Mass., reported total revenues for the second quarter of $19.6 million, of which $17.5 million represented sales of Feraheme (ferumoxytol) in the U.S., a 29 percent increase over sales for the same period last year. Read More
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said data from the LUX-Lung trial program, investigating afatinib in patients with advanced non-small-cell lung cancer (NSCLC), have been published in the Journal of Clinical Oncology. Read More
